| Literature DB >> 31084718 |
Thomas S Bander1, Kishwer S Nehal1, Erica H Lee2.
Abstract
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in the United States. Outcomes are generally favorable, but a subset of cSCC is biologically distinct and requires a different approach because of its higher risk of local recurrence, metastasis, and death. This article focuses on the recent literature regarding identification of this high-risk subset, efforts to validate and improve the prognostic ability of staging systems, and updates in management.Entities:
Keywords: AJCC staging; Cutaneous squamous cell carcinoma; EGFR inhibitor; High-risk skin cancer; PD-1 inhibitor; Sentinel lymph node biopsy; Skin cancer radiologic imaging; Squamous cell carcinoma staging
Mesh:
Year: 2019 PMID: 31084718 DOI: 10.1016/j.det.2019.03.009
Source DB: PubMed Journal: Dermatol Clin ISSN: 0733-8635 Impact factor: 3.478